Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance After RCC Induction in CLL
NCT00718549Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2009
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rituximab in chronic lymphocytic leukemia (CLL) (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Disease Progression (PD), Relapse, or Death Due to Any Cause at 5 years and Progression-Free Survival (PFS) at 5 years. Started Jul 2009; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00718549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718549.